Literature DB >> 30426532

FOXD2-AS1 correlates with the malignant status and regulates cell proliferation, migration, and invasion in cutaneous melanoma.

Wenqing Ren1, Zirong Zhu2, Lina Wu3.   

Abstract

Long noncoding RNA (lncRNA) FOXD2 adjacent opposite strand RNA 1 (FOXD2-AS1) has been shown to be dysregulated in several types of human cancer. However, the role of FOXD2-AS1 in cutaneous melanoma was still unclear. In our study, FOXD2-AS1 expression has been found to be upregulated in cutaneous melanoma tissue specimens and cell lines compared with that in normal tissue specimens and normal human epidermal melanocyte, respectively. Furthermore, high expression of FOXD2-AS1 was obviously correlated with deep Breslow thickness, present ulceration, high Clark level and distant metastasis in cutaneous melanoma patients. However, there were no statistical associations between FOXD2-AS1 expression and cutaneous melanoma patients' disease-free survival and overall survival. The results of loss-of-function study showed that inhibition of FOXD2-AS1 suppresses cutaneous melanoma cell proliferation, migration and invasion through regulating phospho-Akt expression. In conclusion, FOXD2-AS1 is associated with clinical progression in cutaneous melanoma patients, and functions as oncogenic lncRNA in cutaneous melanoma cells.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  FOXD2-AS1; biomarker; cancer; lncRNA; melanoma

Year:  2018        PMID: 30426532     DOI: 10.1002/jcb.27820

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  A novel RNA sequencing-based prognostic nomogram to predict survival for patients with cutaneous melanoma: Clinical trial/experimental study.

Authors:  Jun Tian; Ye Yang; Meng-Yang Li; Yuan Zhang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

2.  Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis.

Authors:  Huasong Liu; Jun Zhang; Xiangyu Luo; Min Zeng; Liqiang Xu; Qunxian Zhang; Hua Liu; Jialong Guo; Lanlan Xu
Journal:  Oncol Res       Date:  2019-09-26       Impact factor: 5.574

Review 3.  Non-coding RNAs in skin cancers:Biological roles and molecular mechanisms.

Authors:  Fei Liu; Shenglong Li
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988

4.  Long Noncoding RNA FOXD2-AS1 Promotes the Malignancy of Cervical Cancer by Sponging MicroRNA-760 and Upregulating Hepatoma-Derived Growth Factor.

Authors:  Xiaoqing Dou; Qun Zhou; Mingxiao Wen; Jiangyan Xu; Yingping Zhu; Shuzhen Zhang; Xianli Xu
Journal:  Front Pharmacol       Date:  2020-01-31       Impact factor: 5.810

Review 5.  The role of FOXD2-AS1 in cancer: a comprehensive study based on data mining and published articles.

Authors:  Yongping Zhang; Chaojie Liang; Yu Zhang; Zhinmin Wang; Ruihuan Li; Zhigang Wei; Jiansheng Guo
Journal:  Biosci Rep       Date:  2020-11-27       Impact factor: 3.840

6.  SFPQ promotes an oncogenic transcriptomic state in melanoma.

Authors:  O Bi; C A Anene; J Nsengimana; M Shelton; W Roberts; J Newton-Bishop; J R Boyne
Journal:  Oncogene       Date:  2021-07-03       Impact factor: 9.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.